Skip to main content
Premium Trial:

Request an Annual Quote

Enzo Biochem to Enter Cytogenetics Market with Single Copy DNA Probes

NEW YORK, May 24 (GenomeWeb News) - Enzo Biochem signed a licensing agreement with Missouri-based Children's Mercy Hospitals & Clinics for cytogenetics technology, the company announced yesterday.

 

Terms of the deal call for Enzo to receive technology involving the application and combination of fluorescence in situ hybridization with human genome sequence information, along with rights to any future related patents. The agreement also gave Enzo rights to approximately 50 DNA probes developed at the University.

 

The agreement allows Enzo to enter the cytogenetics market by producing newly patented single copy DNA probes that can identify the minutest DNA. Enzo will produce the probes in its manufacturing facility in New York and market them worldwide, the company said.

 

The company will combine the probes with its signal amiplification technologies, which will improve visualization levels. Unlike commercially produced DNA probes, which are limited to primarily examining large sections of DNA, single copy DNA probes offer a specificity in hybridizing genetic chromosomes.

 

Financial details were not disclosed.

The Scan

Should've Been Spotted Sooner

Scientists tell the Guardian that SARS-CoV-2 testing issues at a UK lab should have been noticed earlier.

For Martian Fuel

Researchers have outlined a plan to produce rocket fuel on Mars that uses a combination of sunlight, carbon dioxide, frozen water, cyanobacteria, and engineered E. coli, according to Gizmodo.

To Boost Rapid Testing

The Washington Post writes that new US programs aim to boost the availability of rapid at-home SARS-CoV-2 tests.

PNAS Papers on Strawberry Evolution, Cell Cycle Regulators, False-Positive Triplex Gene Editing

In PNAS this week: strawberry pan-genome, cell cycle-related roles for MDM2 and MDMX, and more.